Inflarx N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: data-quality checks not passed.
Price vs value
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Inflarx N.V. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds42 adding, 11 cuttingOf 16 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Revenue growth decelerating: TTM revenue growth slowed to -81.5% (-244.4pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Revenue shrinking. Revenue fell 81.5% over the last 12 months.
- Growth slowing. The growth rate is 244.4 points lower than a quarter earlier.
- Loss-making. Operating margin is -71182.1%: costs exceed revenue.
- Heavy stock-based pay. Stock pay equals 15153.4% of revenue: a real cost that cash-flow figures leave out.
- Share dilution. Diluted shares rose 14.2% in a year.
- Gross margin slipping. Gross margin is down 22777.2 points on a year ago.
Latest results
- Earnings per share
- -$0.09 against an average estimate of -$0.06: missed by 63.6%
- Next report
- November 3, 2026
Price chart
- 1 day+6.3%
- 1 week+12.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $33,162
- Net margin
- -155582.1%
- EPS (TTM, diluted)
- $-0.77
Growth
- Revenue growth
- −81.5%
- Change in growth rate
- −244.4 pts
- Share count change
- +14.2%
Cash
- Stock pay % of revenue
- 15153.4%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for IFRX from the sources we follow. See filings →
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 3, 2026, before the open.
Analysts' consensus
No analyst estimates are published for Inflarx N.V.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.06 | −$0.09 | −63.6% |
| Mar 2026 | −$0.15 | −$0.08 | +45.8% |
| Dec 2025 | −$0.15 | −$0.15 | −2.7% |
| Sept 2025 | −$0.12 | −$0.18 | −46.9% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 9.4% of tradable shares
- Days to cover
- 23.87 at average volume
- Short interest, 1 month
- +5% to October 15, 2026
- Held by institutions
- 70% of shares
- Held by insiders
- 3.0% of shares
- Employees
- 65 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 0 | 0 | 0 |
| Gross profit | −1 | −3 | −8 |
| Operating income | −49 | — | — |
| Net income | −46 | −50 | −52 |
| Diluted EPS | −$0.84 | −$0.84 | −$0.77 |
| Growth (year on year) | |||
| Revenue | — | +162.9% | −81.5% |
| Margins | |||
| Gross margin | −743.7% | <−999% | <−999% |
| Operating margin | <−999% | — | — |
| Net margin | <−999% | <−999% | <−999% |
| Cash flow | |||
| Cash from operations | −41 | −53 | −40 |
| Stock-based pay | 4 | 4 | 5 |
| Balance sheet | |||
| Cash | 14 | 19 | 19 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −14 | −19 | −19 |
| Diluted shares | 55m | 59m | 67m |
Financial health
- Short-term assets cover short-term liabilities $63m of assets due within a year against $15m of liabilities due within a year.
- Short-term assets cover long-term liabilities $63m short-term assets against $795,525 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +14.2%
- year over year
- R&D spending
- 87691.5%
- of revenue
Competitors: side by side with peers
| Last 12 months unless stated | IFRX | LYEL | AIM | IBIO | LSTA | CLDX | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $33162 | $27000 | $95000 | $100000 | $100000 | $158000 | $55m |
| Revenue growth, last 12 months | −81.5% | −55.0% | −21.5% | −75.0% | −90.7% | −97.3% | 12.2% |
| Revenue growth, 3-year average | — | −91.8% | −17.3% | −62.4% | — | −63.5% | 13.7% |
| Revenue growth, latest quarter | — | −50.0% | 4.0% | −100.0% | −100.0% | −97.0% | 10.2% |
| Gross margin | <−999% | — | −968.5% | 59.9% | 7.7% | — | 82.8% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −168.8% |
| Free-cash-flow margin | — | <−999% | <−999% | <−999% | <−999% | <−999% | −162.4% |
| Free-cash-flow margin, 3-year average | — | <−999% | <−999% | <−999% | <−999% | <−999% | −310.0% |
| Stock pay / revenue | >999% | >999% | 0.0% | >999% | >999% | >999% | 20.7% |
| Change in share count | 14.2% | — | 49.8% | 13.9% | 5.1% | 4.7% | 8.3% |
Who owns it
Funds buying and selling- Reported value
- $218M
- Institutions reporting
- 62
- Shares held vs prior quarter
- ▲ 415.8%
- Positions opened / closed
- 29 / 3
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Montanova Capital, LLC | $51.4M | 22.9M | 23.6% | ▲ 189.1% |
| Tcg Crossover Management, LLC | $32.5M | 14.5M | 14.9% | New |
| FMR LLC | $18.3M | 8.2M | 8.4% | New |
| Commodore Capital LP | $16.4M | 7.3M | 7.5% | New |
| Kalehua Capital Management LLC | $13M | 5.8M | 6.0% | New |
| Spruce Street Capital LP | $12M | 5.4M | 5.5% | New |
| 683 Capital Management, LLC | $11.3M | 5.1M | 5.2% | ▲ 52.8% |
| Farallon Capital Management, L.L.C. | $7.4M | 3.3M | 3.4% | — |
| Stempoint Capital LP | $7.2M | 3.2M | 3.3% | New |
| Great Point Partners LLC | $6.8M | 3.0M | 3.1% | New |
| ADAR1 Capital Management, LLC | $6.7M | 3.0M | 3.1% | ▲ 1795.5% |
| Ameriprise Financial Inc | $5.8M | 2.6M | 2.6% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Inflarx N.V.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Inflarx N.V. in brief
- What does Inflarx N.V. do?
- Inflarx N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Inflarx N.V.'s stock ticker?
- Inflarx N.V. trades under the ticker IFRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Inflarx N.V.'s revenue, and how fast is it growing?
- Over its most recent trailing twelve months, Inflarx N.V. reported revenue of $33,162, 81.5% lower than a year earlier, according to its SEC filings.
- Who are Inflarx N.V.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Tcg Crossover Management, LLC and FMR LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Who are Inflarx N.V.'s competitors?
- In our Biotechnology peer group, the companies closest to Inflarx N.V. are Lyell Immunopharma, Inc., AIM Immunotech Inc., Ibio, Inc., Lisata Therapeutics, Inc. and Celldex Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Inflarx N.V.'s.
- When is Inflarx N.V.'s next earnings date?
- Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Inflarx N.V. announces its own schedule.
Follow research on Inflarx N.V.
New research on the companies we cover arrives in the weekly email. Free, one email a week.